

2024 MIPS Seminar Program

 31 Jul 2024

 12:00 pm to 1:00 pm

 LT3

A GUIDED TOUR THROUGH THE WORLD OF REGISTRY-BASED HEALTH RESEARCH: DESTINATION DENMARK.

Kristoffer Jarlov Jensen, MSc, PhD



Kristoffer is a pharmacoepidemiologist at the Copenhagen Phase IV Unit, Center for Clinical Research and Prevention, Copenhagen University Hospital – Bispebjerg-Frederiksberg, Denmark. This centre specializes in registry-based studies of drug safety, efficacy, and utilization, often collaborating with the pharmaceutical industry or regulators.

He has a diverse research background, holding an MSc in Biotechnology from Copenhagen University and a PhD in Vaccine Immunology from the Statens Serum Institut and the University of Southern Denmark. His research training took him to Guinea-Bissau, West Africa, where he participated in clinical trials for an HIV vaccine candidate and phase IV trials for the tuberculosis vaccine BCG at the Bandim Health Project. In one of the poorest countries in the world, Dr. Jensen learned the value of maintaining longitudinal population registries, despite the significant resources required.

During his postdoctoral work at the Technical University of Denmark, he conducted large animal trials and clinical experiments with vaccines. However, he eventually decided to transition to pharmacoepidemiology at the Copenhagen Phase IV Unit after growing tired of handling stubborn pigs and late-night laboratory experiments going wrong.

His talk will focus on the numerous clinical registries covering the entire Danish population that form the basis of their research. He will present parts of the Danish data landscape and infrastructure, and provide examples of research applications. As a generalist, his talk will not be centered around any specific clinical or pharmacological area.

Kristoffer is currently a visiting researcher at the Centre for Medicine Use and Safety, in Health Economics and Policy Evaluation Research led by Zanfina Ademi at Monash University. The purpose of his stay is to acquire skills in health economics, particularly cost-effectiveness analysis and lifetable modelling.